Glenmark Pharmaceuticals has informed that it attached media release today titled ‘Glenmark is the first company to launch in India a Triple FDC of Teneligliptin + Pioglitazone + Metformin for Adults with Type 2 Diabetes & High Insulin Resistance’.
The above information is a part of company’s filings submitted to BSE.